西立伐他汀和国产辛伐他汀对老年高脂血症患者降脂作用的比较

 目的观察西立伐他汀(拜斯亭)的降脂作用，并与国产辛伐他汀(京必舒新)相比较。方法40例高脂血症患者随机分为拜斯亭组(0.3 mg，QN×4周)和京必舒新组(20 mg，QN×4周)，治疗前后分别测定总胆固醇(TC)、总甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)和肝肾功能、血糖、血尿常规等结果拜斯亭降低血清总胆固醇和低密度脂蛋白胆固醇及甘油三酯的作用优于京必舒新，服药后4周上述3个指标分别降低了29.02%，29.95%，17.21%和22.48%，28.68%，14.74%，治疗前后拜斯亭组TC，TG，LDL-C下降的绝对值优于京必舒新组，但组间无差异。观察期间，两组均未出现明显不良反应。结论拜斯亭对老年高脂血症的治疗作用及安全性与京必舒新相同，剂量小，耐受性好。

Clinical comparison of cerivastatin with simvastatin for aged hyperlipidemia

OBJECTIVE To assess the efficacy and safety of Lipobay (cerivastatin) and Jingbishuxin (simvastatin) on lipid profiles.METHODS 40 patients with hypercholesterolemia were randomizedly divided into Lipobay group (0.3 mg,QN) and Jingbishuxin group (domestic simvastatin tablet) (20 mg,QN)for 4 weeks.Total cholesterol (TC),low density Lipoprotein cholesterol (LDL C),triglyceride (TG) and high density lipoprotein cholesterol (HDL C),blood sugar,hepatic and renal function,blood and urine regular test were measured before and after the treatment.RESULTS After 4 weeks of treatment,TC,LDL C and TG were reduced by 29.02%,29.95%,17.21% in Lipobay the group and 22.48%,28.68%,14.74% in Jingbishuxin group,respectively.Compared the measurements after treatment with that before treatment,there were significant differences in both groups,but there was no significant difference between them.No serious adverse effect was found.CONCLUSION Lipobay had a same efficacy and safety on lipoprotein profiles as that of Jingbishuxin in elderly.It has a good tolerance with smaller dose.